Enrollment for The Angel Catheter® Clinical Trial has begun with three patients successfully enrolled. Site Initiation Visits are underway with a goal to include up to 30 U.S. sites in this multicenter, prospective, single arm clinical investigation of the Angel® Catheter. At the successful completion ...
Enrollment Expectations Exceeded in the Pivotal Investigation of the Angel® Catheter and BiO2 Medical Sponsors Massachusetts General PE Symposium
Pivotal Investigation of BiO2 Medical's Angel® Catheter Exceed Enrollment Expectations BiO2 Medical is pleased to announce The Angel® Catheter Clinical Trial is off to an exceptional start with subject ...
BiO2 Medical Executes Full Commercialization in the United Kingdom Partnering with United Drug Medical (UDM) as an Exclusive Distributor for the Angel® Catheter
BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has signed a distribution agreement with Pyramed, a division of United Drug Medical (UDM). This milestone accomplishment grants Pyramed exclusive rights to distribute the Angel® Catheter throughout ...
BiO2 Medical Executes Q4 2013 Commercialization Strategy for the Angel® Catheter, Signing Distribution Partnership Agreements in Key European and Middle Eastern Geographies
BiO2 Medical has achieved Q4 2013 global expansion goals for the Angel® Catheter, a novel Central Venous Catheter (CVC) with a permanently attached retrievable Inferior Vena Cava (IVC) filter to provide Pulmonary Embolism (PE) protection for critically ill patients. The Angel® Catheter is the first ...